Peptide Therapy: Prescribing and Sourcing From Licensed U.S. Pharmacies

Interest in peptide therapy has grown quickly, and the evidence base differs widely from one peptide to the next. Providers who consider peptides should evaluate the evidence for each agent, understand the regulatory landscape, and source medications only through licensed pharmacies.

What Are Peptides?

Peptides are short chains of amino acids that act as signaling molecules. Some peptide drugs, such as insulin and GLP-1 receptor agonists, are FDA-approved and supported by large clinical trials. Other peptides marketed for wellness or performance have limited human data.

Evidence and Regulatory Considerations

• Evidence varies: Review published clinical data for each peptide and indication rather than relying on marketing claims.
• FDA status: Some peptides are approved drugs, some are restricted from compounding, and others are not approved for human use. Providers are responsible for understanding current FDA and state board requirements.
• Not for research use: Products labeled "research use only" or sold without a prescription are not appropriate for patient care.
• Informed consent: Patients should understand the evidence level, potential risks, and whether a use is off-label.

Why Pharmacy Sourcing Matters

When a peptide is clinically appropriate, it should be prescribed by a licensed provider and dispensed by a licensed U.S. pharmacy. Pharmacy oversight is intended to support quality standards, proper labeling, and accountability for the products patients receive.

Questions to Ask a Pharmacy Partner:

• Is the pharmacy licensed in the states where patients reside?
• What quality, sterility, and testing standards does it follow for compounded preparations?
• How are active ingredients sourced and documented?
• What patient counseling and provider support are available?

Patient Selection and Monitoring

As with any therapy, peptide prescribing should follow an appropriate evaluation, a documented treatment plan, defined goals, and scheduled follow-up. Therapy should be reassessed or discontinued if goals are not met or adverse effects occur.